H. Pylori: What It Is, What It Destroys, And How To Get Rid Of It

H. Pylori And Cardiovascular Disease

The cardiovascular connections are real, but require honest presentation because the data is conflicting.

Atrial Fibrillation

A significant body of evidence links H. pylori to atrial fibrillation (AF), one of the most common cardiac arrhythmias affecting approximately 2.2 million Americans.

The initial observation came from cardiologists who noticed that a high proportion of AF patients admitted to their department had concurrent gastric complaints and high H. pylori seropositivity. R

In a pilot study, H. pylori seropositivity and CRP were both significantly higher in AF patients compared to controls, with persistent AF patients showing even higher levels than paroxysmal AF patients.

A 943-patient study found that younger patients (under 50) who were H. pylori seropositive had a notably higher relative risk of AF than seronegative peers, though this association weakened after adjusting for confounders including age. R

A 2025 review summarizes proposed mechanisms including systemic inflammation via IL-6 and CRP elevation, gut microbiome disruption affecting the gut-heart axis, metabolic dysregulation (altered LDL and HDL from H. pylori), and a specific molecular mechanism involving autoantibodies against H+/K+-ATPase cross-reacting with cardiac Na+/K+-ATPase, potentially disrupting cardiac ion homeostasis. R

The honest caveat: a meta-analysis found weak correlation between H. pylori and AF that did not reach statistical significance after meta-regression. R

The relationship is associative, biologically plausible, and probably real in a subset of AF patients, but H. pylori is not established as an independent causal factor for AF the way it is for peptic ulcers.

Eradicating H. pylori in a patient with AF and confirmed infection is still appropriate and reasonable.

Coronary Artery Disease

Multiple studies associate H. pylori (particularly CagA-positive strains) with coronary heart disease, atherosclerosis, and adverse lipid profiles (elevated LDL, reduced HDL, elevated triglycerides). R

The proposed mechanism is chronic systemic inflammation driving endothelial damage and accelerating atherosclerotic plaque formation.

Again, the data is associative and conflicting across studies.

The clearest signal is the inflammatory pathway: H. pylori raises CRP and inflammatory cytokines, and chronic systemic inflammation from any cause accelerates cardiovascular disease.

How To Eradicate H. Pylori

Pharmaceutical Triple Or Quadruple Therapy

Standard triple therapy consists of a proton pump inhibitor (PPI) twice daily plus two antibiotics (clarithromycin and amoxicillin, or clarithromycin and metronidazole) for 10-14 days.

Eradication rates with triple therapy have declined to approximately 70-80% in many regions due to rising antibiotic resistance, particularly to clarithromycin and metronidazole. R

Current consensus states that if clarithromycin resistance in a region exceeds 15%, triple therapy should be abandoned in favor of bismuth quadruple therapy or alternative regimens. R

Bismuth quadruple therapy (PPI + bismuth + tetracycline + metronidazole) achieves higher eradication rates (85-90%) and is preferred in areas with high clarithromycin resistance. R

Bismuth has direct anti-H. pylori activity via disruption of cell walls and enzyme inhibition, and also provides mucosal protection.

Confirmation of eradication is essential and should be done at least 4 weeks after completing treatment using a C13 urea breath test or stool antigen test (not serology, which can remain positive for years after successful eradication).

Natural And Functional Medicine Protocol

Natural protocols are appropriate as standalone approaches for lower-burden infections without aggressive virulence factors, as adjuncts to pharmaceutical therapy to increase eradication rates, or for patients who have failed or cannot tolerate antibiotics.

The evidence is honest here: natural agents used alone have significantly lower eradication rates than pharmaceutical triple therapy (typically 30-40% vs 70-90%) in published trials.

They are most effective when combined with pharmaceutical therapy or when used in structured, adequate-duration protocols.

Mastic Gum

Mastic gum is a resin from Pistacia lentiscus, native to the island of Chios in Greece, with centuries of use for stomach complaints.

It has documented direct bactericidal activity against H. pylori at concentrations achievable in the stomach, including activity against clarithromycin-resistant and metronidazole-resistant strains. R

In a randomized pilot study, mastic gum alone (1g/day and 3g/day for 14 days) achieved eradication in approximately 30-38% of patients, compared to 77% for pharmaceutical triple therapy. R

A 2023 study in the American Journal of Clinical Pathology found that adding mastic gum to modified triple therapy significantly improved eradication rates compared to triple therapy alone. R

Mucosal Repair After Eradication

Eradicating H. pylori is only half the work.

The gastric mucosa, parietal cells, and intestinal barrier have all been damaged by months to years of infection and inflammation.

Repair is required.

DGL continues to be useful post-eradication for mucosal healing.

Zinc Carnosine: 75mg twice daily for 60-90 days post-eradication accelerates mucosal restoration.

L-Glutamine: the preferred fuel for intestinal epithelial cells; 5g twice daily supports barrier repair. R

Colostrum: contains growth factors (IGF-1, EGF, TGF-beta) that directly stimulate gastric mucosal regeneration. R

Probiotics: Lactobacillus acidophilus and Bifidobacterium longum alongside S. boulardii support microbiome reconstitution after eradication and antibiotic use.

Betaine HCl: once eradication is confirmed and significant gastric healing has occurred (typically 6-8 weeks post-treatment), restoring gastric acid with betaine hydrochloride supplements helps normalize B12, iron, and calcium absorption that hypochlorhydria had impaired.

Nutrient repletion: B12, iron, folate, magnesium, and calcium should all be assessed and supplemented as indicated given the documented depletion from H. pylori-associated hypochlorhydria.

What To Stay Away From

• NSAIDs (ibuprofen, naproxen, aspirin) during active H. pylori infection or treatment: NSAIDs damage the gastric mucosal barrier independently, and the combination of H. pylori and NSAID use dramatically increases peptic ulcer risk
• Alcohol: damages gastric mucosa, inhibits mucosal healing, and may reduce antibiotic efficacy during treatment
• High-salt diet: significantly exacerbates H. pylori virulence and accelerates the progression from gastritis to gastric cancer; high salt diet is an independent risk factor for gastric cancer, and H. pylori and high salt appear to act synergistically R
• Serology to confirm eradication: H. pylori IgG antibodies remain elevated for months to years after successful eradication; post-treatment testing must use the C13 urea breath test or stool H. pylori antigen test, not serology
• Proton pump inhibitors used long-term without addressing the underlying H. pylori: PPIs reduce symptoms without clearing the infection, and long-term PPI use itself causes hypochlorhydria with the same downstream nutrient depletion consequences as the infection itself; it is common for H. pylori to be missed because the patient's symptoms are suppressed by PPIs
• Relying on natural agents alone for CagA-positive, high-virulence infections: the risk profile of CagA-positive strains (gastric cancer, severe peptic ulcer disease) justifies the higher eradication rates achievable with pharmaceutical triple or quadruple therapy; natural protocols are appropriate adjuncts but should not substitute for pharmaceutical therapy in high-virulence presentations
• Treating the patient without treating household contacts: H. pylori transmits within families via oral-oral and fecal-oral routes; untreated household contacts are the most common source of reinfection; when one family member tests positive, screening other household members is clinically appropriate

Testing

First-Line Testing

PCR-based stool testing via the GI-MAP (Diagnostic Solutions) is the test of choice for H. pylori in functional medicine because it provides:

• Quantitative H. pylori load (not just positive/negative)
• All seven virulence factors (BabA, CagA, CagPAI, DupA, IceA, OipA, VacA) in a single result
• Comprehensive picture of the full gut ecosystem alongside the H. pylori result (dysbiosis, other pathogens, inflammatory markers, digestive function)

The Gut Zoomer (Vibrant Wellness) also detects H. pylori via multiplex PCR alongside full microbiome analysis, intestinal permeability markers, and gut immune function.

Conventional Testing Options

C13 urea breath test is the non-invasive gold standard for both initial diagnosis and post-treatment eradication confirmation.

The patient swallows C13-labeled urea; if H. pylori is present, its urease converts the labeled urea to C13-labeled CO2 that appears in exhaled breath.

Sensitivity and specificity are both above 95%.

This test must be performed at least 4 weeks after completing antibiotic therapy and at least 2 weeks after stopping PPIs to avoid false negatives.

Stool antigen test (HpSA) detects H. pylori proteins directly in stool via enzyme immunoassay.

Sensitivity is approximately 94% and specificity 97% for initial diagnosis.

Also appropriate for post-treatment confirmation.

Endoscopy with biopsy: rapid urease test (CLO test) on biopsy tissue, histology, and culture from endoscopy.

Culture allows antibiotic sensitivity testing, which is increasingly valuable given rising clarithromycin and metronidazole resistance rates.

Serology (H. pylori IgG): useful for initial epidemiological screening but not for confirming eradication; antibodies persist for months to years after clearance.

Downstream Consequence Testing

When H. pylori is confirmed, always assess:

CBC with Differential: anemia pattern (hypochromic microcytic for iron deficiency, macrocytic for B12 deficiency), neutropenia as a sign of concurrent infection burden.

Vitamin B12 and Folate: both commonly depleted by H. pylori-associated hypochlorhydria.

Iron Studies + Ferritin: ferritin is the most sensitive marker of iron stores; low ferritin in the presence of H. pylori is a combination that confirms iron-deficiency contribution from the infection.

Nutrient Zoomer (Vibrant Wellness): most comprehensive option if a full micronutrient picture is needed, covering B12, folate, iron, magnesium, calcium, vitamin C, and zinc alongside full vitamin and mineral panel.

Foundation Zoomer (Vibrant Wellness): baseline liver function, CBC, CMP, and iron studies in a single panel.

Mechanisms Of Action

Simple:

• H. pylori produces urease to neutralize stomach acid locally, allowing it to survive in an environment designed to kill bacteria, then burrows into the protective mucus layer of the stomach where immune cells cannot reach it.
• By damaging the acid-producing parietal cells, H. pylori progressively reduces stomach acid, which in turn blocks the absorption of vitamin B12, iron, calcium, magnesium, and folate because all of these require gastric acid for their release or solubility.
• The bacteria injects a toxin called CagA directly into stomach cells, hijacking their signaling pathways and driving uncontrolled cell growth that, over decades, can progress to gastric cancer.
• The chronic inflammation from H. pylori degrades the tight junctions between intestinal cells, creating leaky gut that allows food antigens into the bloodstream and triggers food sensitivities, skin problems, and autoimmune reactions.
• Mastic gum kills H. pylori by disrupting its cell membrane through its acidic resin fractions; vitamin C neutralizes H. pylori urease, stripping away its acid-defense shield; zinc carnosine supports mucosal repair while zinc provides a direct antimicrobial environment.

Advanced:

• Urease mechanism and ammonium buffering: H. pylori urease is a nickel-containing multi-subunit enzyme (UreAB) with extraordinary catalytic capacity, producing enough ammonia to buffer the immediate microenvironment to pH 6-7 even in a pH 2 stomach. H. pylori also expresses UreI, an inner membrane proton-gated urea channel that opens only at low pH, ensuring ammonia production precisely when acid exposure increases. The resulting ammonium ions are directly toxic to gastric epithelial cells (contributing to mucosal damage) while simultaneously protecting the bacteria. R
• CagA T4SS injection and oncogenesis: The Cag pathogenicity island (Cag PAI) encodes a type IV secretion system (T4SS), a molecular syringe that contacts the host cell surface and directly injects CagA protein into the cytoplasm. Once inside, CagA is phosphorylated at EPIYA motifs by Src and Abl kinases. Phosphorylated CagA binds and activates SHP2 phosphatase, which drives sustained ERK activation and the "hummingbird phenotype" (elongated cell morphology, increased motility). Unphosphorylated CagA disrupts E-cadherin-beta-catenin complexes, activating Wnt/beta-catenin transcription and driving proliferative gene expression. CagA also activates NF-kB through interaction with TAK1 and LUBAC, and disrupts PAR1 polarity kinase, causing loss of epithelial architecture. Collectively, these effects simultaneously promote inflammation, cell proliferation, and loss of tumor suppressor function. R
• Iron competition and hepcidin modulation: H. pylori competes directly for host iron, which it requires for growth and virulence gene expression. It expresses lactoferrin-binding proteins (HopQ, AlpAB) and produces siderophores to scavenge iron from the gastric environment. In parallel, H. pylori infection stimulates liver hepcidin production through IL-6-dependent JAK-STAT3 signaling. Hepcidin causes ferroportin internalization and degradation on macrophages, hepatocytes, and enterocytes, trapping iron intracellularly and reducing serum iron availability. This creates functional iron deficiency through two simultaneous mechanisms: impaired dietary iron absorption from hypochlorhydria, and hepcidin-mediated restriction of iron release from stores. R
• Mastic gum mechanism: The active anti-H. pylori fraction of mastic gum is its acidic resin components, particularly isomasticadienolic acid and oleanolic acid. These triterpenic acids disrupt H. pylori cell membrane integrity through detergent-like insertion into the lipid bilayer, causing cell morphology abnormalities (blebbing, cellular fragmentation) visible by electron microscopy at sub-bactericidal concentrations. They also inhibit DNA gyrase (topoisomerase II) in H. pylori, blocking DNA replication. Notably, mastic gum appears active against metronidazole-resistant and clarithromycin-resistant strains, making it a meaningful adjunct when antibiotic resistance reduces pharmaceutical efficacy. R
• Vitamin C and urease inhibition: Ascorbic acid at concentrations achievable in gastric juice (physiological intragastric vitamin C is approximately 100-250 mcmol/L in healthy individuals but suppressed to near zero in H. pylori infection) directly inhibits H. pylori urease activity through oxidation of the essential cysteine residue in the active site. Without functional urease, H. pylori cannot buffer pericosmic pH, loses its acid resistance, and cannot maintain colonization in the gastric antrum. Vitamin C also stimulates gastric mucus production and mucosal immunity. The direct suppression of gastric vitamin C by H. pylori is itself a virulence mechanism that removes this natural chemical defense. R

More Research

• H. pylori is carried by approximately 50% of the global population and causes over 90% of duodenal ulcers and approximately 80% of gastric ulcers; it is classified as a Group 1 definite carcinogen by IARC and is the primary modifiable cause of gastric adenocarcinoma. R
• Virulence factor testing via the GI-MAP changes clinical decision-making: a CagA-positive, VacA-positive infection carries substantially higher risk for peptic ulcers and gastric cancer than a virulence-factor-negative infection, and the urgency and aggressiveness of eradication should reflect this stratification.
• Iron-deficiency anemia that fails to respond to iron supplementation should prompt H. pylori testing even in the absence of gastrointestinal symptoms; the combination of iron deficiency and H. pylori is common and the anemia will not resolve while the infection persists. R
• Post-treatment confirmation of eradication is not optional: a meaningful proportion of patients who complete a full antibiotic course fail to eradicate H. pylori due to resistance, non-compliance, or incomplete bacterial killing; the C13 urea breath test at 4-6 weeks post-treatment is the standard confirmation method. R
• Adding mastic gum, DGL, berberine, zinc carnosine, vitamin C, allicin (garlic), and/or Saccharomyces boulardii to pharmaceutical triple therapy consistently improves eradication rates and reduces antibiotic-related side effects across multiple RCTs; a meta-analysis of allicin specifically found an eradication rate of 93.8% vs 83.6% in the control arm (OR = 2.75, p < 0.001), and a meta-analysis of S. boulardii found significantly improved eradication rates and reduced side effects across 18 RCTs with 3,592 patients. R R
• H. pylori eradication is a first-line intervention for H. pylori-associated ITP: the molecular mimicry mechanism between CagA and platelet surface glycoproteins drives anti-platelet autoantibody production, and eradication removes the antigen source; long-term follow-up studies show platelet recovery sustained 7 or more years post-eradication in responding patients. R
• A meta-analysis confirmed that H. pylori infection correlates with both Graves' disease and Hashimoto's thyroiditis, and that H. pylori eradication reduces thyroid autoantibodies; CagA-positive strains carry the strongest association with thyroid autoimmunity through molecular mimicry with thyroperoxidase. R
• The Correa cascade from H. pylori infection to gastric cancer is well-characterized and takes decades, but eradication at any point in the non-atrophic or early atrophic gastritis stage can halt or reverse the progression; once intestinal metaplasia is established, cancer risk persists even after eradication, requiring endoscopic surveillance. R
• Household contact screening is clinically appropriate after any confirmed H. pylori diagnosis; reinfection from an untreated household member is a common reason eradication protocols fail to prevent recurrence.
• For comprehensive gut assessment when H. pylori is suspected, the GI-MAP provides H. pylori quantification, full virulence factor panel, co-pathogen screening, dysbiosis mapping, and inflammatory markers in one result, making it the most clinically informative single test available.